ABSTRACT

Introduction Allogeneic bone-marrow transplantation (BMT) has been the standard treatment of patients with acute myeloid leukaemia (AML) for the last 15 years. The procedure was initially used only in patients with advanced or refractory disease because of its toxicity. However, even in these poor-risk cases, long-term survival was shown to be possible in 10-15% [1].